KOREA PHARMA Co., Ltd. (KOSDAQ:032300)

KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 144.73 billion. The enterprise value is 151.97 billion.

Market Cap	144.73B
Enterprise Value	151.97B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 29, 2025

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 16.03% in one year.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	+16.03%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	63.38%
Owned by Institutions (%)	0.01%
Float	3.99M

Valuation Ratios

The trailing PE ratio is 100.01.

PE Ratio	100.01
Forward PE	n/a
PS Ratio	1.70
PB Ratio	2.04
P/TBV Ratio	2.15
P/FCF Ratio	n/a
P/OCF Ratio	38.17
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.79, with an EV/FCF ratio of -8.47.

EV / Earnings	104.92
EV / Sales	1.78
EV / EBITDA	17.79
EV / EBIT	27.48
EV / FCF	-8.47

Financial Position

The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.53.

Current Ratio	1.71
Quick Ratio	1.16
Debt / Equity	0.53
Debt / EBITDA	5.42
Debt / FCF	-2.10
Interest Coverage	1.25

Financial Efficiency

Return on equity (ROE) is 2.05% and return on invested capital (ROIC) is 2.36%.

Return on Equity (ROE)	2.05%
Return on Assets (ROA)	2.01%
Return on Invested Capital (ROIC)	2.36%
Return on Capital Employed (ROCE)	4.53%
Revenue Per Employee	636.85M
Profits Per Employee	10.81M
Employee Count	134
Asset Turnover	0.70
Inventory Turnover	2.38

Taxes

Income Tax	-366.76M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.46% in the last 52 weeks. The beta is 1.24, so KOREA PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.24
52-Week Price Change	-15.46%
50-Day Moving Average	13,716.20
200-Day Moving Average	14,655.45
Relative Strength Index (RSI)	42.71
Average Volume (20 Days)	10,506

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 85.34 billion and earned 1.45 billion in profits. Earnings per share was 132.69.

Revenue	85.34B
Gross Profit	34.58B
Operating Income	3.93B
Pretax Income	1.08B
Net Income	1.45B
EBITDA	6.95B
EBIT	3.93B
Earnings Per Share (EPS)	132.69

Balance Sheet

The company has 30.38 billion in cash and 37.62 billion in debt, giving a net cash position of -7.24 billion or -663.99 per share.

Cash & Cash Equivalents	30.38B
Total Debt	37.62B
Net Cash	-7.24B
Net Cash Per Share	-663.99
Equity (Book Value)	71.04B
Book Value Per Share	6,512.99
Working Capital	28.46B

Cash Flow

In the last 12 months, operating cash flow was 3.79 billion and capital expenditures -21.74 billion, giving a free cash flow of -17.95 billion.

Operating Cash Flow	3.79B
Capital Expenditures	-21.74B
Free Cash Flow	-17.95B
FCF Per Share	-1,645.89

Margins

Gross margin is 40.52%, with operating and profit margins of 4.61% and 1.70%.

Gross Margin	40.52%
Operating Margin	4.61%
Pretax Margin	1.27%
Profit Margin	1.70%
EBITDA Margin	8.14%
EBIT Margin	4.61%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.36%.

Dividend Per Share	50.00
Dividend Yield	0.36%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	37.65%
Buyback Yield	-16.03%
Shareholder Yield	-15.67%
Earnings Yield	1.00%
FCF Yield	-12.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 3.19 and a Piotroski F-Score of 6.

Altman Z-Score	3.19
Piotroski F-Score	6